Resource Type Archives - Page 59 of 126

Nice develops medtech innovation briefing for Xstrahl distributed xoft axxent electronic brachytherapy system

NICE (National Institute for Health and Care Excellence) has announced a new Medtech Innovation Briefing (MIB)1 stating that NHS doctors and commissioners may consider Single Dose Intraoperative Radiotherapy (SD-IORT) using Xstrahl distributed Xoft Axxent eBx as a treatment option for early stage breast cancer patients. A single dose of intraoperative radiotherapy (IORT) is an effective and convenient alternative to daily conventional radiotherapy for appropriate early stage breast cancer patients.

Use of Protoporphyrin Fluorescence to Determine Clinical Target Volume for Non-melanotic Skin Cancers Treated with Primary Radiotherapy

PURPOSE: Non-melanotic skin cancers remain the most commonly diagnosed cancers. Radiotherapy and surgery are the most common treatment options. Radiotherapy has a recurrence rate of up to 20% for basal or squamous cell cancers. One of the difficulties is to determine...

MRI-guided radiotherapy of the SK-N-SH neuroblastoma xenograft model using a small animal radiation research platform

OBJECTIVE: Neuroblastoma has one of the lowest survival rates of all childhood cancers, despite the use of intensive treatment regimens. Preclinical models of neuroblastoma are essential for testing new multimodality protocols, including those that involve...

Validating clinical practice using SARRP; simulating clinical radiotherapy in a model mimicking spontaneous occurring NSCLC

Over 60% of cancer patients worldwide will receive radiotherapy as a part of their overall treatment plan. Recently, stereotactic body radiation therapy (SBRT) has been recognized as a favorable treatment option for those cancer types that remain inoperable. SBRT administers very high doses of radiation in a small number of fractions, and has been shown to achieve 3-year control rates of roughly 90% in stage 1 NSCLC’s.

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma

Background The radiopharmaceutical 131I-meta-iodobenzylguanidine (131I-MIBG) is an effective treatment for neuroblastoma. However, maximal therapeutic benefit from 131I-MIBG is likely to be obtained by its combination with chemotherapy. We previously reported enhanced...

Xstrahl In Action: Quantitative bioluminescence tomography using spectral derivative data

Bioluminescence imaging (BLI) is a non-contact, optical imaging technique based on measurement of emitted light due to an internal source, which is often directly related to cellular activity. It is widely used in pre-clinical small animal imaging studies (such as...

Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma

AIM: Small, solitary hepatocellular carcinoma is curable with stereotactic radiation or other methods of tumor ablation, however, regional and systemic tumor recurrence occurs in over 70% of patients. Here we describe the ability of immunoradiotherapy to induce an...

$Modelling responses to spatially fractionated radiation fields using preclinical image-guided radiotherapy$

Modelling responses to spatially fractionated radiation fields using preclinical image-guided radiotherapy

OBJECTIVE: Radiotherapy is planned to achieve the optimal physical dose distribution to the target tumour volume whilst minimizing dose to the surrounding normal tissue. Recent in vitro experimental evidence has demonstrated an important role for intercellular...

Kinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine (FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET for the Fiscrimination between High-Grade Glioma and Radiation Necrosis in Rats

Background Discrimination between glioblastoma (GB) and radiation necrosis (RN) post-irradiation remains challenging but has a large impact on further treatment and prognosis. In this study, the uptake mechanisms of 18F-fluorodeoxyglucose (18F-FDG),...

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Resource Type

Find out more about how Xstrahl will work tirelessly for you

Explore Related Categories

OUR COMPANY

RECENT NEWS

Advancements in Translational Research: Dr. Karl Butterworth, Queen’s University Belfast

Xstrahl in Action: Xstrahl 300 Used to Treat NMSC with Hypofractionated Radiotherapy

Xstrahl in Action: SARRP Enables Precise and Localized Ablation in Neurogenesis Studies

Join Our Newsletter